From personalized dosing to on-demand production, explore how digital tablets are transforming pharma. Join us for a webinar on July 22 to see what's next.
In this Q&A, Ingenza CEO Nick Challoner, discusses how CRDMOs must evolve to help biotech companies accelerate development, reduce risk, and translate scientific innovation into scalable commercial success.
Advances in payload-linker technology have made ADCs a major therapeutic modality, prompting drug developers to strive for greater selectivity and safety in the next wave of ADCs.
In this Contract Pharma VideoBite, Evotec’s team reveals how flexible innovation is unlocking improved solubility and bioavailability for complex molecules across modern drug development.
Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specializing in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.
PLD Pharma Services is a full-service CDMO providing end-to-end development and manufacturing for oral and solid dose Rx and OTC drugs across multiple delivery systems. With comprehensive R&D and analytical labs, an extensive formulation library, and a portfolio of more than 60 ANDAs, PLD supports products in solids, liquids, lozenges, and gummies. Backed by three decades of expertise, our integrated team advances programs from early concept through scale-up and commercial launch—all within a single, integrated team.
